Multiple therapeutic approaches targeting IL-23 or IL-17 have garnered clinical approval, thereby further underscoring the importance of the IL-23/IL-17 axis in the pathogenesis of psoriasis [14]. This evidence concerns the gene IL17A and psoriasis.